A prospective validation dataset just landed in Nature Medicine that every MASLD trial team should have open alongside their protocol. The LITMUS Imaging Study delivers head-to-head performance data on imaging and serum diagnostic biomarkers for steatohepatitis and fibrosis in metabolic dysfunction-associated steatotic liver disease, and the signal it sends to clinical operations is unambiguous: the era of defaulting to liver biopsy as the only credible endpoint anchor is ending, but the replacement options are not interchangeable.

The stakes here are structural. Resmetirom (Rezdiffra) received accelerated approval in March 2024 based on histological endpoints derived from liver biopsies, making it the first approved therapy for noncirrhotic MASH with moderate-to-advanced fibrosis. That approval was a milestone, but it also exposed the core operational problem: biopsy-dependent trials are slow, expensive, patient-hostile, and prone to sampling variability. Nine randomized controlled trials in MASH cirrhosis reviewed in a 2025 systematic analysis showed only a minority meeting their predefined primary endpoints, with investigators pointing directly at surrogate endpoint limitations as a contributing factor. The field has known it needs better tools. LITMUS is the most rigorous attempt yet to prove which tools are actually ready.

What the Validation Data Actually Shows

The LITMUS Imaging Study enrolled an estimated 300 participants across prospective sites, with data collection running from March 2020 through an estimated completion of December 2026. Publishing interim validation findings now, in July 2026, means the dataset is mature enough to draw regulatory-grade conclusions about biomarker performance, even as the full cohort follow-up continues.

The comparison that matters most for trial designers involves magnetic resonance elastography against transient elastography. Prior validation work had already flagged a performance gap: MRE achieved an AUROC of 0.82 for detecting any fibrosis stage versus transient elastography’s AUROC of 0.67, a difference that reached statistical significance at P = 0.0116. The LITMUS dataset now extends this comparison into a prospectively designed, multi-biomarker framework that includes serum panels alongside imaging, which is the combination sponsors actually need to evaluate when they are building a monitoring strategy for an 18- or 24-month adaptive trial.

This is where the operational implication becomes concrete. Sponsors who assumed transient elastography and MRE were functionally equivalent for fibrosis staging in their protocols were working with an assumption the data no longer supports. A 15-point AUROC gap translates directly into misclassified patients, diluted treatment effect signals, and failed trials.

The Regulatory Accelerant

The FDA accelerated this pressure point in June 2025 when it accepted a Letter of Intent to qualify Liver Stiffness Measurement by Vibration-Controlled Transient Elastography (LSM by VCTE) as a reasonably likely surrogate endpoint for clinical trials in adults with non-cirrhotic MASH and moderate-to-advanced fibrosis. That acceptance signals the agency’s willingness to receive accelerated approval packages built on imaging biomarker data rather than biopsy histology, but it comes with a critical qualifier: the qualification pathway requires the biomarker to perform to a defined evidentiary standard.

That is exactly the gap LITMUS was designed to close. A biomarker qualification submission without prospective validation data in the target population is a filing that will not survive a complete response letter. The LITMUS dataset gives sponsors something to point to: a rigorously designed, independently validated performance profile for both imaging modalities and serum markers in a MASLD-specific cohort, collected under conditions that mirror multi-site trial operations rather than single-center academic research.

The serum biomarker findings deserve separate attention. Prior evidence had established FIB-4-based algorithms as cost-effective for population screening, with an incremental cost-effectiveness ratio of $74,596 per QALY in adults aged 40 to 49 years undergoing routine medical check-ups in the United States. But cost-effectiveness in a screening context does not automatically translate to regulatory-grade endpoint sensitivity in a randomized trial. LITMUS tests both in parallel, which means sponsors can now disaggregate screening utility from endpoint utility and make protocol decisions accordingly.

Rewriting Your Endpoint Strategy Before Monday

If you are running a Phase 2 or Phase 2b MASLD trial using transient elastography as your primary fibrosis endpoint without a pre-specified sensitivity analysis anchored to MRE, your statistical analysis plan has a gap that a FDA reviewer will find. The LITMUS data creates an evidentiary record that reviewers can and will cite when evaluating whether a sponsor’s imaging endpoint was selected with adequate scientific justification. The old posture of “TE is standard practice” no longer functions as a regulatory defense when the peer-reviewed literature now includes a prospective head-to-head dataset demonstrating the performance differential.

Practically, this means three immediate protocol conversations. First, if your sites are TE-only equipped, you need a feasibility assessment of MRE access within a reasonable patient travel radius, because FDA’s surrogate endpoint acceptance framework for LSM by VCTE will not automatically accommodate an inferior modality just because it is more widely deployed. Second, if you are relying on a serum panel as a secondary endpoint, the LITMUS serum performance data should be reviewed against your specific patient population characteristics before you lock your statistical analysis plan. Third, if you are designing a decentralized or hybrid trial in MASLD, the logistical asymmetry between imaging and serum biomarker collection becomes a central operational variable, not a footnote.

The broader pipeline is watching this closely. Multiple GLP-1-based combinations and FXR agonists are currently in Phase 2 MASLD development, and their sponsors are making endpoint decisions now that will define their Phase 3 registration strategies. The LITMUS dataset is the most current prospective validation reference available for those decisions, which means it will almost certainly appear in Type B meeting briefing packages before the end of 2026.

Watch the FDA’s Biomarker Qualification Program docket between now and Q1 2027. The LSM by VCTE Letter of Intent acceptance is the opening move. The LITMUS publication is the evidentiary response. What comes next is a formal qualification submission, and the agency’s review timeline on that submission will determine whether the next wave of MASLD Phase 3 trials launches on biopsy endpoints or on imaging biomarkers that patients can actually tolerate being measured with.

References

  1. Nature Medicine — “Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study”
  2. FDA — “FDA Accepts Proposal for Reasonably Likely Surrogate Endpoint for MASH”
  3. ClinicalTrials.gov — LITMUS Imaging Study, NCT05479721
  4. PMC — MRE vs. Transient Elastography AUROC Comparison for Liver Fibrosis
  5. UIC Drug Information Group — Resmetirom (Rezdiffra) Accelerated Approval, March 2024
  6. Journal of Clinical Medicine — Systematic Review: Endpoint Validation Challenges in MASH Cirrhosis Trials
  7. PMC — Cost-Effectiveness of FIB-4-Based Screening for Advanced Fibrosis in MASLD
  8. PMC — MASLD Treatment Landscape: Resmetirom and Pipeline Review, 2024-2025
Website |  + posts

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.